WS #16582
In contrast to the tech rout, several healthcare and industrial companies reported strong third-quarter results. Regeneron Pharmaceuticals beat estimates with an adjusted EPS of $20.07, driven by robust demand for its metabolic and weight-loss drug portfolio. nVent Electric also exceeded expectations with a 44% year-over-year revenue growth, benefiting from data center infrastructure demand. These earnings highlight that while hardware manufacturing is struggling, downstream applications in healthcare and specialized industrial infrastructure remain resilient.
Pharma and Industrial Earnings Beats
In contrast to the tech rout, several healthcare and industrial companies reported strong third-quarter results. Regeneron Pharmaceuticals beat estimates with an adjusted EPS of $20.07, driven by robust demand for its metabolic and weight-loss drug portfolio. nVent Electric also exceeded expectations with a 44% year-over-year revenue growth, benefiting from data center infrastructure demand. These earnings highlight that while hardware manufacturing is struggling, downstream applications in healthcare and specialized industrial infrastructure remain resilient.